Stockscreener 앱 받기
10.20
4.62%
0.45
시간 외 거래:
10.23
0.03
+0.29%
전일 마감가:
$9.75
열려 있는:
$10.24
하루 거래량:
2,730
Relative Volume:
0.26
시가총액:
$110.04M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.39%
1개월 성능:
-24.44%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$9.60
$10.24
1주일 범위
$8.86
$10.78
52주 변동 폭
$8.86
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
명칭
Exozymes Inc
전화
(626) - 415 - 1488
주소
750 ROYAL OAKS DR, MONROVIA
EXOZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
10.20 | 110.04M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Exozymes Inc 주식(EXOZ)의 최신 뉴스
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast - ACCESS Newswire
Exozymes (NASDAQ:EXOZ) Issues Quarterly Earnings Results - MarketBeat
eXoZymes Inc. Reports Q1 2025 Highlights and NCTx Launch - TipRanks
Earnings call transcript: eXoZymes Q1 2025 unveils innovation and market strategy - Investing.com Australia
Exozymes Q1 2025 Earnings Call Transcript - MarketBeat
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today - Stock Titan
eXoZymes develops AI-driven approach to produce rare nutraceutical compound - World Bio Market Insights
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST - Stock Titan
eXoZymes Launches Spin-Out, NCTx, To Unlock A Promising Compound For Gut And Liver Health - SynBioBeta
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health - ACCESS Newswire
Revolutionary Liver Health Compound Finally Achievable: How AI Platform Solved 30-Year Production Challenge - Stock Titan
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - ADVFN
eXoZymes creates AI-engineered enzymes for biomanufacturing - Scientific Computing World
eXoZymes Inc. Introduces 'Exozymes' Terminology in Cover Story of GEN Biotechnology to Advance Cell-Free Biomanufacturing - Nasdaq
Bringing clarity and precision to the cell-free space by introducing exozymes | Daily Guardian - dailyguardian.ca
Bringing clarity and precision to the cell-free space by introducing exozymes - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), a - ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Newswire :) Press Release Distribution
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice - Yahoo Finance
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Tacoma News Tribune
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vic - ACCESS Newswire
EXoZymes Inc. Announces Its Latest Initiative BioClick - MarketScreener
eXoZymes appoints Damien Perriman as Chief Commercial Officer - World Bio Market Insights
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
eXoZymes Inc. (EXOZ) reports earnings - Quartz
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Big News Network.com
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
Exozymes Inc (EXOZ) 재무 분석
Exozymes Inc (EXOZ)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Exozymes Inc 주식 (EXOZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Heltzen Michael | Chief Executive Officer |
Jan 16 '25 |
Buy |
10.72 |
121 |
1,297 |
2,105 |
| Heltzen Michael | Chief Executive Officer |
Nov 15 '24 |
Buy |
11.10 |
1,984 |
22,022 |
1,984 |
1.45%
0.86%
자본화:
|
볼륨(24시간):